AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
← catalyst calendarNCT06991114 · readout ≤ 530 d
Sponsored by Artiva Biotherapeutics, Inc. (industry) · ARTV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
90estimated
Sites
52
Countries
Brazil, Bulgaria, France +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-09 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Refractory Rheumatoid Arthritis (RA)
- Idiopathic Inflammatory Myopathies (IIMs)
- Systemic Sclerosis (SSc)
- Rheumatoid Arthritis (RA
- IIM
- Myositis
- Scleroderma
- Sjogren Syndrome
- Sjogrens Disease
Intervention
- Drug: Allogeneic NK Cells
Primary outcome
what the primary-completion date above is the date OFSafety
measured From enrollment until the end of treatment at Week 104.
Permalink · ARTV's whole pipeline · Catalyst calendar · Every registered study · What changed